156 related articles for article (PubMed ID: 8774570)
41. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
42. [Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
Zielińska E; Zubowska M; Bodalski J
Pol Merkur Lekarski; 2003 Apr; 14(82):295-8. PubMed ID: 12868187
[TBL] [Abstract][Full Text] [Related]
43. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
44. Assessment of chemotherapy-associated nephrotoxicity in children with cancer.
Skinner R; Pearson AD; Coulthard MG; Skillen AW; Hodson AW; Goldfinch ME; Gibb I; Craft AW
Cancer Chemother Pharmacol; 1991; 28(2):81-92. PubMed ID: 2060086
[TBL] [Abstract][Full Text] [Related]
45. Renal toxicity and chemotherapy in children with cancer.
Ruggiero A; Ferrara P; Attinà G; Rizzo D; Riccardi R
Br J Clin Pharmacol; 2017 Dec; 83(12):2605-2614. PubMed ID: 28758697
[TBL] [Abstract][Full Text] [Related]
46. Long-term nephrotoxicity in adult survivors of childhood cancer.
Dekkers IA; Blijdorp K; Cransberg K; Pluijm SM; Pieters R; Neggers SJ; van den Heuvel-Eibrink MM
Clin J Am Soc Nephrol; 2013 Jun; 8(6):922-9. PubMed ID: 23411430
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
48. Hypophosphataemic rickets after ifosfamide treatment in children.
Sweeney LE
Clin Radiol; 1993 May; 47(5):345-7. PubMed ID: 8508598
[TBL] [Abstract][Full Text] [Related]
49. Ifosfamide nephrotoxicity in paediatric cancer patients.
Ashraf MS; Brady J; Breatnach F; Deasy PF; O'Meara A
Eur J Pediatr; 1994 Feb; 153(2):90-4. PubMed ID: 8157032
[TBL] [Abstract][Full Text] [Related]
50. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
[TBL] [Abstract][Full Text] [Related]
51. Nephrotoxicity associated with ifosfamide.
Smeitink J; Verreussel M; Schröder C; Lippens R
Eur J Pediatr; 1988 Nov; 148(2):164-6. PubMed ID: 3234441
[TBL] [Abstract][Full Text] [Related]
52. Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Rossi RM; Kist C; Wurster U; Külpmann WR; Ehrich JH
Pediatr Nephrol; 1994 Apr; 8(2):151-6. PubMed ID: 8018491
[TBL] [Abstract][Full Text] [Related]
53. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.
Ashraf MS; Skinner R; English MW; Craft AW; Pearson AD
Med Pediatr Oncol; 1997 Jan; 28(1):62-4. PubMed ID: 8950339
[TBL] [Abstract][Full Text] [Related]
54. Strategies to prevent nephrotoxicity of anticancer drugs.
Skinner R
Curr Opin Oncol; 1995 Jul; 7(4):310-5. PubMed ID: 7578377
[TBL] [Abstract][Full Text] [Related]
55. Ifosfamide nephrotoxicity in children: histopathological features in two cases.
Morland BJ; Mann JR; Milford DV; Raafat F; Stevens MC
Med Pediatr Oncol; 1996 Jul; 27(1):57-61. PubMed ID: 8614393
[TBL] [Abstract][Full Text] [Related]
56. The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors.
Kooijmans ECM; van der Pal HJH; Pluijm SMF; van der Heiden-van der Loo M; Kremer LCM; Bresters D; van Dulmen-den Broeder E; van den Heuvel-Eibrink MM; Loonen JJ; Louwerens M; Neggers SJC; Ronckers C; Tissing WJE; de Vries ACH; Kaspers GJL; Veening MA; Bökenkamp A;
Kidney Int; 2022 Nov; 102(5):1136-1146. PubMed ID: 35772499
[TBL] [Abstract][Full Text] [Related]
57. Influence of age upon Ifosfamide-induced nephrotoxicity.
McCune JS; Friedman DL; Schuetze S; Blough D; Magbulos M; Hawkins DS
Pediatr Blood Cancer; 2004 May; 42(5):427-32. PubMed ID: 15049014
[TBL] [Abstract][Full Text] [Related]
58. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
MacLean FR; Skinner R; Hall AG; English M; Pearson AD
Cancer Chemother Pharmacol; 1998; 41(5):413-6. PubMed ID: 9523738
[TBL] [Abstract][Full Text] [Related]
59. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
60. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
